DoD Prostate Cancer, Clinical Consortium Award

The Department of Defense (DOD) through the U.S. Army Medical Research and Development Command (USAMRDC) and Congressionally Directed Medical Research Programs (CDMRP) has announced the FY25 Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA), funding opportunity number HT942525PCRPCCA. This initiative supports the development and maintenance of a robust clinical research infrastructure to rapidly execute phase 2 and phase 1/2 prostate cancer clinical trials. The intent is to combine the efforts of leading investigators across multiple institutions to advance innovative therapeutic interventions, ultimately decreasing the burden of prostate cancer, particularly among high-risk populations such as military personnel and Veterans. The PCRP was established in 1997 and has received a total of $2.37 billion through FY24, with FY25 appropriations set at $75 million. This CCA offers support to both a Coordinating Center and multiple Clinical Research Sites. The Coordinating Center, which also functions as a Clinical Research Site, will manage the consortium’s administrative structure, support clinical protocol execution, and integrate affiliate sites, especially those with access to high-risk and/or military patient populations. Each Clinical Research Site will be responsible for trial execution, including patient recruitment, data collection, and adherence to the consortium’s standard operating procedures. The CDMRP expects to allocate approximately $10.5 million to fund one Coordinating Center and $22 million to fund approximately eleven Clinical Research Sites, each with a budget cap of $2 million over a four-year period. Matching funds are not required. Funding covers personnel, regulatory support, trial coordination, data systems, communications, and meeting costs. Notably, the Coordinating Center must incorporate and support at least two affiliate sites with a minimum of $250,000 per site per year, and must provide two pre-funded clinical trial protocols ready for execution within the first three months of award. Eligibility extends to both intramural DOD organizations and extramural entities including academic institutions, for-profit and nonprofit organizations, and foreign entities. Principal Investigators must be independent researchers with a faculty-level appointment or equivalent. All applications must be submitted through a two-step process involving a pre-application (letter of intent) via the eBRAP portal and a full application via either eBRAP (for DOD applicants) or Grants.gov (for non-DOD applicants). The pre-application deadline is August 11, 2025, at 5:00 p.m. ET, and the full application deadline is September 2, 2025, at 11:59 p.m. ET. Applications will be evaluated through a two-tiered review process: peer review for technical merit and programmatic review for alignment with the PCRP’s overarching challenges. These include reducing deaths from prostate cancer, improving treatment outcomes, enhancing quality of life, and increasing access to care—especially for high-risk and underserved populations. Additional requirements include a detailed project narrative, a comprehensive budget, and plans for sustainability, compliance with FDA and IRB regulations, and data sharing. For assistance, applicants can contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507. Grants.gov users may reach out to support@grants.gov or 800-518-4726. All applicants are advised to begin registrations early as delays can hinder timely submission. Awards will be made by September 30, 2026, with funds available for use until September 30, 2031.

Strong emphasis on experience, metrics, and sustainability planning.